| 1. |
|
|
| 2. |
- Borisov, S, et al.
(författare)
-
Surveillance of adverse events in the treatment of drug-resistant tuberculosis: first global report
- 2019
-
Ingår i: The European respiratory journal. - : European Respiratory Society (ERS). - 1399-3003 .- 0903-1936. ; 54:6
-
Tidskriftsartikel (refereegranskat)abstract
- The World Health Organization (WHO) recommends that countries implement pharmacovigilance and collect information on active drug safety monitoring (aDSM) and management of adverse events.The aim of this prospective study was to evaluate the frequency and severity of adverse events to anti-tuberculosis (TB) drugs in a cohort of consecutive TB patients treated with new (i.e. bedaquiline, delamanid) and repurposed (i.e. clofazimine, linezolid) drugs, based on the WHO aDSM project. Adverse events were collected prospectively after attribution to a specific drug together with demographic, bacteriological, radiological and clinical information at diagnosis and during therapy. This interim analysis included patients who completed or were still on treatment at time of data collection.Globally, 45 centres from 26 countries/regions reported 658 patients (68.7% male, 4.4% HIV co-infected) treated as follows: 87.7% with bedaquiline, 18.4% with delamanid (6.1% with both), 81.5% with linezolid and 32.4% with clofazimine. Overall, 504 adverse event episodes were reported: 447 (88.7%) were classified as minor (grade 1–2) and 57 (11.3%) as serious (grade 3–5). The majority of the 57 serious adverse events reported by 55 patients (51 out of 57, 89.5%) ultimately resolved. Among patients reporting serious adverse events, some drugs held responsible were discontinued: bedaquiline in 0.35% (two out of 577), delamanid in 0.8% (one out of 121), linezolid in 1.9% (10 out of 536) and clofazimine in 1.4% (three out of 213) of patients. Serious adverse events were reported in 6.9% (nine out of 131) of patients treated with amikacin, 0.4% (one out of 221) with ethionamide/prothionamide, 2.8% (15 out of 536) with linezolid and 1.8% (eight out of 498) with cycloserine/terizidone.The aDSM study provided valuable information, but implementation needs scaling-up to support patient-centred care.
|
|
| 3. |
|
|
| 4. |
|
|
| 5. |
|
|
| 6. |
|
|
| 7. |
|
|
| 8. |
|
|
| 9. |
|
|
| 10. |
- Di Benedetto, M. D., et al.
(författare)
-
Wireless ventilation control for large-scale systems : The mining industrial case
- 2009
-
Ingår i: 2009 6th IEEE Annual Communications Society Conference on Sensor, Mesh and Ad Hoc Communications and Networks Workshops. - 9781424439386
-
Konferensbidrag (refereegranskat)abstract
- Mining ventilation is an interesting example of a large scale system with high environmental impact where advanced control strategies can bring major improvements. Indeed, one of the first objectives of modern mining industry is to fulfill environmental specifications [1] during the ore extraction and crushing, by optimizing the energy consumption or the production of polluting agents. The mine electric consumption was 4 % of total industrial electric demand in the US in 1994 (6 % in 2007 in South Africa) and 90 % of it was related to motor system energy [2]. Another interesting figure is given in [3] where it is estimated that the savings associated with global control strategies for fluid systems (pumps, fans and compressors) represent approximately 20 % of the total manufacturing motor system energy savings. This motivates the development of new control strategies for large scale aerodynamic processes based on appropriate automation and a global consideration of the system. More specifically, the challenge in this work is focused on the mining ventilation since as much as 50 % or more of the energy consumed by the mining process may go into the ventilation (including heating the air). It is clear that investigating automatic control solutions and minimizing the amount of pumped air to save energy consumption (proportional to the cube of airflow quantity [4]) is of great environmental and industrial interest.
|
|
